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Abstract
Human leishmaniasis is a major public health problem with a wide clinical 
spectrum. Despite there is an epidemiological diversity of the disease, cases mostly 
occur in the developing countries around the subtropical region, and the incidence 
is significantly rising. The disease is usually classified into three groups: cutaneous 
leishmaniasis, mucosal leishmaniasis, and visceral leishmaniasis. But to ensure their 
survival in different conditions, Leishmania spp. have developed many adaptation 
mechanisms and can be seen in different clinical forms as well. Herein, an overview of 
the characteristics of the disease and the parasite, interactions with the host, clinical 
aspects, and latest developments in the diagnosis and treatment is presented.
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1. Introduction
Human leishmaniasis is a sandfly-mediated parasitic disease that can lead to 
severe conditions in individuals especially with underdeveloped immune system. 
It usually affects people living in developing tropical countries and has high mor-
tality rates [1]. Transmission of the parasite starts with an infected sandfly bite. 
After getting bit by a female sandfly vector carrying the promastigote form of the 
Leishmania protozoan, the promastigotes transform into amastigote form in mam-
malian hosts [2]. Once amastigotes enter the cells, immune system starts reacting to 
it. Phagocytes absorb the parasite, and destructive mechanism is initiated in order 
to kill the parasite. However, parasite has different ways of preventing or lowering 
the activity of immune system, and three distinct forms of leishmaniasis can be 
observed as a result which are cutaneous leishmaniasis (CL), visceral leishmani-
asis (VL), and mucocutaneous leishmaniasis (ML). CL usually occurs around the 
uncovered sites such as face, neck, and extremities which are susceptible to sandfly 
bite and often can result in the formation of ulcers or nodules around exposed areas. 
In certain conditions, macrophages infected by the parasites at the initial bite site 
spread among the reticuloendothelial system causing VL. Abnormal growth of 
internal organs such as the spleen and liver is common in VL, and it can cause death 
if necessary treatment methods are not applied. Another form of leishmaniasis is 
the ML in which parasites enter the mucocutaneous tissue, and its effects are usually 
seen around the oral and upper respiratory tract [3].
Leishmaniasis is considered to be an endemic disease effecting more than 98 
countries with a global prevalence of 12 million people. Among different types of 
disease, CL makes up great percentage of the total amount of cases compared to other 
two. East Africa, Brazil, and Indian subcontinent are hot spots for VL cases, whereas 
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CL cases are high in the Middle East, Mediterranean region, Central Asia, and Latin 
American countries [4]. In European countries where leishmaniasis is not endemic, 
people traveling to endemic regions for various reasons such as military duty, tourism 
work, and vacation are the major cause of leishmaniasis occurrence [5].
There are more than 20 Leishmania species responsible from leishmaniasis [3]. 
In general, Leishmania major causes CL, Leishmania donovani causes VL, and 
Leishmania infantum results in both CL and VL [3]. These species can be further 
classified into subgenera depending on anatomical varieties of infection sites. Old 
World sandfly species are common in desert and semidry areas, whereas New 
World sandfly species transmit the disease to human near forest habitation [6]. 
Leishmania parasite has promastigote form in sandfly and amastigote form in mam-
malians. It can be transmitted by the vectors from an animal carrying this parasite 
or humans affected by VL. Amastigotes develop within the phagocytes and spread 
to other macrophages as a result of cell lysis. Once a sandfly bites an infected host, 
amastigotes then transform into promastigote form inside the sandfly restarting the 
transmission process for the next host that will be infected.
Leishmaniasis is ranked second in mortality right after malaria and ranked 
fourth in terms of morbidity among other communicable diseases [2]. HIV out-
break in the 1990s resulting in HIV/VL coinfection and general global warming of 
the world increasing the possible habitat for the sandfly led to doubling the amount 
of cases from 1987 to 2014 despite developing medical technologies [6]. It is esti-
mated that each year around 400,000 people are having VL with a mortality rate 
of 10% going up to 20% in some areas [2, 3]. The Mediterranean region, Western 
Asia, and the Americas make up the 90% of 1 million CL cases, whereas ML is 
represented by 35,000 cases in these regions [3]. Among the other common forms 
of the disease, CL has the highest amount of cases reported each year. On the other 
hand, VL is the most fatal one where death usually occurs 2 years after the first 
transmission.
There are 98 countries and territories with Leishmania cases recorded each year 
[7]. It affects around 12 million people worldwide, and 1.5–2 million new cases are 
reported each year. Being an ignored tropical disease, leishmaniasis has the high-
est prevalence in poor countries such as India, Brazil, Ethiopia, and Afghanistan. 
Notably, there has been an increase in the CL case reports for Syria in the Middle 
East, Algeria in the Mediterranean, and India [6]. Poor housing, insufficient sanitary 
conditions, poor waste management, poverty, malnutrition, and change in climate 
conditions such as temperature, rainfall, and humidity are common features of 
these countries. Children living in these countries are considered the main reason of 
parasite transmission as they are the most vulnerable population group to sandfly bite.
Among species, L. major shows the biggest geographical distribution in the Middle 
East region compared to Leishmania tropica and Leishmania infantum [8]. L. infantum 
caused zoonotic and L. tropica caused anthroponotic transmissions to occur. Domestic 
dogs, rodents, and wild animals in endemic regions hold epidemiological importance 
as they take part in transmission of the parasite by serving as reservoirs.
Parasites can only reach infective stages in certain species of sandfly which as a 
result limits its transmission [9]. In addition, parasite-vector contact is rare for great 
majority of the sandfly species [10]. Epidemiological concerns about the leishmani-
asis have increased greatly in the last 30 years. HIV/Leishmania coinfection, sand-
flies becoming more apparent in areas that they were less present such as the United 
States and Canada, and great risk of Leishmania gaining resistance to drugs over 
time make it a high-risk factor globally [11]. Another major concern for leishmani-
asis is the increased resistance gain by parasite to current treatment methods which 
makes it even more dangerous considering there is an ongoing effort to develop a 
human vaccine against the disease [12].
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Here, we aim to provide a general conceptualization of leishmaniasis by summa-
rizing the historical development of the disease to provide a better understanding 
for possible future approaches.
2. History of the disease
In 1885, after observing Leishmania organism for the first time, Cunningham 
stated that the organism was not a bacteria. Thirteen years later, a Russian mili-
tary surgeon Peter Borovsky further found out that the organism was a protozoan 
which was also confirmed by Wright in 1903. During that time, William Leishman 
and Charles Donovan described the agent responsible from VL. Leishman 
conducting his study in India observed enlargement of the spleen and fever in 
patients which he further observed the samples he took from the patients under 
the microscope using Romanowsky method for staining and stated that it was 
not like anything he had seen before [13]. Finally, in 1942, female phlebotomine 
sandflies had enough evidence to be accepted as the main vector for CL and VL 
due to the fact that clinical conditions observed following a sandfly bite described 
as histiocytoses [14]. In terms of changing face of diagnosis of leishmaniasis, 
starting from the microscopical identification of the agents, medical technologies 
have progressed in time further into PCR-based DNA sequencing methods for 
determination of specific species.
L. donovani was the first identified Leishmania species taking its name from 
William Leishman and Charles Donovan which was given by Ross in order to give 
credit to their studies [15].
Despite being a neglected tropical disease, our knowledge about the disease 
has been increasing continuously. Case reports involving uncommon laryngeal 
leishmaniasis- and HIV-infected individuals showing leishmaniasis effects such as 
skin lesions and nodules have shown that leishmaniasis can occur again even after 
treatment hinting to the incubation period of parasite (Figure 1) [16, 17].
Figure 1. 
A rare case of treated laryngeal ML which originated from a previous CL of hands and feet. Isolated agent is 
L. infantum in this 81-year-old male patient resident in Adana, Turkey, a subtropical area. (a) CL lesions 
on a patients hand on his first application to clinic. (b) CL lesions on patients foot on his first application to 
clinic. (c) BT of neck showing papillomatous push elongating into ventricles. (d) Histological examination 
of laryngeal biopsy specimen (May-Grunwald-Giemsa staining; original magnification, ×1000) showing 
intracellular amastigotes of Leishmania species and histiocytes with vacuolated cytoplasm and corpuscles 
inside. (e) Laryngoscopic examination showing lesions with edema and erythema due to ML. Reprinted 
from [16].
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Treatment of leishmaniasis started with the use of pentavalent antimonials in 
the 1940s. Parasite gaining resistance and high level of toxicity for these drugs made 
it necessary to find an alternative. Amphotericin B is an alternative drug that has 
been in use since 1980. The main action mechanism of amphotericin B is to interfere 
with the membrane lipids and cause disruption. The length of the therapy changes 
between 15 and 45 days for different cases, whereas dosage can vary. Combinatorial 
use of this drug with some other drugs has shown great increase in the effectiveness 
of treatment.
3. Epidemiology
Leishmaniasis is a globally common disease that affects more than 98 countries 
and territories. Even though its effects are mainly observed in underdeveloped 
or developing countries, this parasite has spread to Europe and the United States 
due to the traveling to these areas and immigration from these areas. Old World 
leishmaniasis is endemic in Asia, Africa, the Mediterranean, and the Middle East. 
L. tropica, L. major, Leishmania aethiopica, and L. donovani are the four common 
species causing Old World leishmaniasis. New World leishmaniasis is caused by the 
Leishmania mexicana, Leishmania braziliensis, and Leishmania guyanensis. In total, 
six Old World countries (Afghanistan, Algeria, Arabian Peninsula, Syria, Sudan, 
and Iran) and two New World countries (Brazil and Peru) make up 90% of all 
leishmaniasis reports [18].
Poor process of record taking in underdeveloped and developing countries 
makes it difficult to determine its incidence and prevalence in certain areas. Syria is 
reported to have highest amount of incidence in the Middle East with 52,983 cases 
being reported in 2012 [19]. In Iraq, leishmaniasis had a prevalence of 45.5 cases per 
100,000 of population in 1992 due to the war and population migration which can 
give an estimate of current situation [19].
In Asia, Afghanistan, Iran, and Syria are the three Middle Eastern countries 
where CL is endemic and reported most. Syria having the most amount of CL cases 
also named the disease as Aleppo boil [20]. Moving toward Eastern Asia, Pakistan 
holds great number of CL cases, whereas India and Bangladesh can be considered 
as the sole reservoir for VL [7]. In China, there are three defined VL types: anthro-
ponotic VL, which is caused by L. donovani; zoonotic mountain-type zoonotic 
VL; and zoonotic desert-type VL in which both are caused by L. İnfantum [21]. 
Depending on the habitat, there are four vectors when it comes to VL transmission 
in China [21]: Phlebotomus chinensis and Phlebotomus longiductus for anthroponotic 
VL in domiciliary habitats, P. chinensis for mountain-type zoonotic VL in wild and 
peridomestic habitats, and Phlebotomus wui and Phlebotomus alexandri for zoonotic 
desert-type VL in wild habitats [21].
In Africa, three Leishmania species, L. infantum, L. major, and L. tropica, are 
responsible from the CL cases [8]. Egypt, Algeria, Morocco, Tunisia, and Libya 
are the Northern African countries with the highest amount of reported CL cases 
between 2003 and 2009 [7]. Among East Africa, countries such as Ethiopia, Sudan, 
and Somalia have highest number of reported VL cases between years 2004 and 
2009, which contribute to a large portion of total amount of 8569 cases in the 
region [7]. In Cameroon, survey done in Mokolo region consisting of 32,466 people 
showed 146 active CL lesions and 261 people having scars probably as a result of 
prior CL infection [22]. Interestingly, it was also noted that 4.8% of the patients 
with CL observed to be positive for HIV infection [22].
Realizing the importance of leishmaniasis in most of the African countries 
is a challenge compared to other countries because of the low quality healthcare 
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services, poor data management, and absent reports. East Africa and sub-Saharan 
Africa are the geographical regions where leishmaniasis was the least common 
until 2012 [7]. Considering leishmaniasis is endemic in these regions, it is safe to 
say that observed value will be much different than the real outcome once enough 
data are gathered.
When it comes to Europe, countries in the Mediterranean region such as Italy, 
Greece, Turkey, and Albania have highest prevalence of VL cases [7]. In addition, 
few number of VL cases were observed in France, Spain, Portugal, and Croatia [7]. 
In terms of CL cases, Turkey holds great percentage of reports compared to others. 
In the Netherlands, 185 CL, 8 VL, and 2 MCL cases were observed between 2005 and 
2012 [23]. In general, traveling to endemic regions such as Afghanistan or Morocco 
is shown as a significant risk factor of Leishmania cases in developed countries. Due 
to the nature of leishmaniasis infection, developed European countries have low 
amount of reported cases, and in most of the cases, insufficient immune system is 
the other most important risk factor in addition to trips to endemic regions [24].
American region has low VL and high amount of CL cases reported in general 
with a 1–20 difference. Brazil has the highest amount of reported cases both in VL 
and CL. Colombia, Peru, Nicaragua, and Venezuela are other areas where CL cases 
happen frequently [7].
Mexico, the United States, and Canada have relatively low amount of reported 
cases in terms of global occurrence. A total of 811 CL and 7 VL cases were reported 
in Mexico between 2004 and 2008. The US Army Forces going to endemic regions 
such as Afghanistan for military duty resulted in few reported Leishmania cases in 
the United States.
Australia and Antarctica are the two continents where leishmaniasis is not con-
sidered to be endemic [2]. Between the years 2008 and 2014, 52 CL and 3 VL cases 
were reported in Australia [25]. Traveling to Leishmania parasite endemic regions 
is thought to be the reason for most of these cases as similar with the cases seen in 
Europe [25]. L. tropica was identified in 30 patients and was the highest compared 
to 4 other identified species [25].
4. Transmission and prevention
Only vector responsible for transmitting leishmaniasis is the female sandfly, 
belonging to the genera Phlebotomus spp. in the Old World and Lutzomyia spp. in the 
New World [3]. Out of the many known sandfly species, 93 of them are known to 
spread leishmaniasis. Sandflies are usually active during night time, and they have lim-
ited ability to move. They are usually 2 mm large and are capable of tearing the skin in 
order to feed on blood. Mainly observed in the tropical regions, they have spread to the 
Northern European regions due to the increasing temperatures and climate changes.
Transmission can be zoonotic or anthroponotic depending on the reservoir. 
Domestic dogs are considered to be the major reservoir for zoonotic transmission. 
In the Americas and Central Asia, interaction between wild animals and humans 
also causes zoonotic transmission. Humans with VL or post kala-azar dermal 
leishmaniasis serve as the only reservoir in anthroponotic transmission.
Attenuated parasite vaccines that will provide long-term immunity and prevent 
transmission are in development. Zoonotic transmission occurs with dogs, and 
treatment methods targeting infected dogs are not preferred due to the fact that it 
may result with increased resistance for parasite or there is a high chance of infec-
tion in the nature even after the treatment [6]. Deltamethrin-treated collars were 
tested for the control of the disease and a significant reduction in infection levels in 
dogs was observed [6]. Avoiding outdoor areas in endemic areas, using protective 
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clothing, using insect repellents, covering around the bed with a net, sleeping above 
the ground level, and avoiding night time activities are some of the useful methods 
in order to prevent transmission in humans.
5. Host-parasite interactions
Once Leishmania enters the human host, macrophages try to attack Leishmania 
with reactive oxygen and nitrogen molecules. Leishmania parasite produces prote-
ase with increased activity which considerably lowers macrophage activity. Inside 
the cell, phagosomes consume the parasite, but they are ineffective against the 
parasite as a result of parasite changing the destructive properties of phagosome.
Protective immune response to leishmaniasis mainly depends on the T-cell 
subset response accompanied with the specific cytokines, transcription factors, 
presenting of antigen, and production of various interleukins having direct or 
indirect effect on the main immune system. However, it is important to note that 
susceptibility or resistance to leishmaniasis is possible in individuals with altered 
genetics or depending on the environmental conditions as well as parasite strain 
starting the infection [26].
Immune response starts with the cells of innate immune system. Neutrophils are 
the first immune system cells responding to the sandfly bite starting the leishmani-
asis infection [27]. Neutrophils are capable of producing microbicidal factors effec-
tive against Leishmania such as nitric oxide (NO) and neutrophil extracellular traps 
[27, 28]. Neutrophils are effective protective agent in most forms of the leishmaniasis, 
but this is usually affected by the host genetics and Leishmania strain effecting the 
host [27]. Neutral killers are also recruited to the site of infection after neutrophils, 
and their cytotoxic activity is effective against parasite by mediating lysis [29, 30]. 
Organ-specific protection during the early stages of infection is the case for natural 
killer T cells [31]. Increased natural killer T-cell concentration during the disease 
progress and decreased concentration following treatment indicates importance in 
early response [32]. T cells also play an important role in immune response. Nitric 
oxide production in order to fight with the parasite is induced by IFN-γ-producing 
Th1 cells [27]. However, Th2 is responsible from the susceptibility because of its abil-
ity to produce cytokines such as IL-4 and IL-13 [27]. The regulatory T cells maintain a 
critical role in IL-10 expression and continuity of parasite immunity [27, 33].
Leishmania parasites have developed their own way in order to reduce the effec-
tiveness of immune system. Modifying toll-like receptors’ pathogen recognition 
ability, delaying phagosomes ability to terminate parasite once consumed, altering 
macrophage antigen presentation, and modifying host signaling in order to effect 
production or inhibition of certain cytokines or chemokines such as IL-10 and IL-12 
are some of the examples of immune evasion mechanisms used by parasites [27]. 
Being a progressive disease, increased concentrations of IFN-γ and TNF-α cytokines 
indicate immunosuppressive mechanism for leishmaniasis especially in VL [34–37]. 
IL-10, which is produced by many immune system cells such as B cells, T-cell sub-
sets, and innate cells, is a regulatory cytokine responsible from immune suppression 
and reducing the effectiveness of antigen-presenting cells like macrophages and 
dendritic cells where initial response mainly depends on this process [34]. For VL, 
IL-10 was found to be majorly produced by CD4 + CD25-Foxp3- cells in the spleen 
suggesting that suppression of antileishmanial immunity in effected individuals 
depends on the expression of IL-10 by T cells. In addition, experiments done with 
mouse models have shown that IL-12 signaling and presence of high antigen dose 
can lead to the activation of Th1 cells which coexpresses IL-10 [38]. IL-27 is another 
immune system regulator which promotes T cells to produce IL-10 following an 
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infection [39]. Furthermore, upregulation of IL-21 by T cells in order to reach 
elevated levels of IL-10 is thought to be the role of IL-27 [40]. In order to determine 
immune system cells responsible from the production of IL-10 and IL-27, splenic 
aspirate cells obtained from the VL spleen was tested for expression levels of mRNA 
for various cells. CD14+ cells were found to be main source of IL-27-related mRNA 
expression, whereas CD3+ T cells were the main source of both IL-10 and IL-21 
[40]. For CL, mouse models showed that IL-22 plays a critical role in the progres-
sion of pathology such that increased levels of IL-22 help maintain skin integrity 
and prevent further inflammation [41].
IFN-γ is another important immune system molecule produced by parasite-
dependent Th1 CD4+ lymphocytes and is related to intracellular control of para-
sites upon infection. On the other hand, Th2 CD4+ cells are responsible from the 
progression of the disease. This difference in Th1 and Th2 cell line responses was 
further confirmed by Holaday et al.’s study done on mouse models carrying specific 
mutations. The study showed that in the presence of antigen, Th1-like cell line 
response was to produce IL-2 and IFN-γ, whereas Th2-like cell line response was to 
produce IL-4 and IL-5 upon stimulation [42].
In another study, Th1, Th2, and Th17 CD4+ T-cell subsets were found to induce 
production of IL-10 despite having different signaling pathways and transcription 
route. ERK1 and ERK2 transcriptional activation was common in all these Th cell 
subsets. c-Maf is an important transcription factor in macrophages for the process 
of IL-10 expression and was also found to be common for the previously mentioned 
three different T-cell subsets. c-Maf expression was also found to be dependent on 
ERK activation in Th1 and Th17 cells [38].
6. Clinical characteristics of the disease in humans
Cutaneous leishmaniasis is the milder form of leishmaniasis and usually leads to 
formation of skin lesions or nodules around the exposed bite sites such as face, neck, or 
limbs [8, 24]. Lesions can heal spontaneously in few months, or in some extreme cases, 
it can take few years to resolve [8]. Although CL is self-curing and nonlife-threatening, 
accumulation of CL often leads to disfigured formations on skin. Lesion number can 
vary between 1 and 20, and upon healing, distinct scars are left on the skin. Various 
treatment methods are used in order to speed up the healing process for CL.
Depending on the disease forms observed clinically such as uncomplicated 
form, chronic recurrent form, and diffuse form, there are four causative pathogens 
in the Old World and five causative pathogens in the New World [18]. L. major, L. 
tropica, L. infantum, and L. aethiopica are the pathogens of Old World, whereas L. L. 
mexicana, L. L. amazonensis, L. V. braziliensis, L. V. guyanensis, and L. V. panamensis 
are the pathogens of New World in the case of CL [18].
VL also known as kala-azar is the fatal form of leishmaniasis with a mortal-
ity rate of 75–95%. Macrophages affected by the parasite spread the infection 
throughout the body, and patients develop pancytopenia and immunosuppression 
[6, 43, 44]. VL is often discussed together with HIV as they both affect immune 
system heavily making patients susceptible to other infections. Incubation period 
is between 2 weeks and 2 years. Liver- and spleen-related problems are common in 
patients with VL.
Parasite spreading around the initial bite site using the lymphatic way and 
infecting the nose or mouth mucosa leads to ML (Figure 1) [45]. Immune system 
reacting to parasite at the tip of the nose effects airway walls causing lumen obstruc-
tion which is related to necrosis of the cartilage in the nose. Unlike CL, ML is not a 
self-healing disease and can cause permanent skin problems. Destruction of the tip 
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of the nose is a severe condition that may affect patients in their social life. Breathing 
problems are common result of ML in patients due to the blocked airways [46].
Another form of the disease, post kala-azar dermal leishmaniasis is a complica-
tion of VL in which patients cured of VL develops nodular, macular, or maculo-
papular rash on skin as a result of immune suppression following VL. It is mainly 
observed in Sudan and India where majority of the VL cases progress into post 
kala-azar dermal leishmaniasis [47].
7. Treatment and resistance in humans
There are various treatment methods depending on the host immune system 
effectiveness and the type of Leishmania effecting the host as well as the way 
parasite is transmitted. Host factors such as genetics or immune response or fac-
tors related to treatment such as dosage, duration, and completion of the therapy 
and finally factors related to the parasite, such as intrinsic sensitivity of the spe-
cies and lack of resistance to the medication are important determinants regard-
ing to treatment of the disease. Long incubation period of Leishmania parasite 
makes it a challenge in detection and early treatment methods. If applicable early 
treatment should be applied in order to further prevent the spreading of the 
parasite. Having no effective human vaccines puts the disease at a critical point.
Pentavalent antimonials, sodium stibogluconate and N-methylglucamine, 
liposomal amphotericin B, miltefosine, and paramycin are some of the widely used 
drugs in routine treatment [6, 48]. Compared to liposomal amphotericin B which is 
a less toxic form, conventional amphotericin B has complicated application proce-
dure and harmful side effects making liposomal amphotericin B a better choice in 
treatment of both CL and VL which is also an antifungal agent. Still in some under-
developed or developing countries that cannot afford liposomal amphotericin B 
treatment, pentavalent antimonials are used. Despite their toxic effects on the liver 
and kidneys, pentavalent antimonials are still highly effective [49]. On the other 
hand, emerging resistance limits the therapy frequently. Miltefosine is another drug 
with known effect of inducing parasite resistance if not used properly.
Global antibiotic resistance problem has emerged in the treatment of leishmani-
asis too, and a number of papers reporting treatment failures are increasing [50]. 
Anthroponotic transmission is the main cause of drug resistance in Leishmania 
species. Humans being the anthroponotic host, various effects can lead to drug 
resistance for parasite once treatment starts. Ignoring the recommended consuming 
amount and frequency of the drug, reduced concentration of the drug effecting 
the parasite, inhibition of drug activation, inactivation of active drug, and altera-
tions in host gene amplifications are some important example mechanisms for 
parasites gaining drug resistance. Although, the mechanisms of drug resistance 
in Leishmania species are not well elucidated in detail, but the involvement of 
P-glycoprotein (Pgp)-like ABC transporters and ldmdr1 gene has been detected in 
hard-to-treat parasites [51–54]. In addition, high amount of thiol levels was found 
to play a role in developing resistance as they prevent reduction of pentavalent 
antimonials to trivalent antimonials [55].
8. Latest developments in the diagnosis, prevention, and treatment
Permanent solution for the leishmaniasis in terms of successful human vaccina-
tion is still a major challenge. However, there are different vaccinations currently 
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being tested in mouse model. One of them uses “killed but metabolically active” 
parasites to induce host immune system reaction. Mice infected by “killed but meta-
bolically active” L. infantum chagasi showed no signs of organomegaly or parasite 
presence 6 months after infection compared to mice infected with live parasite. 
Finally “killed but metabolically active” L. infantum chagasi has also shown to 
induce parasite-specific protective host immune response that is similar to response 
induced by live Leishmania [56].
Using salivary peptides of the sandfly holds potential to be used as a vaccine 
component; however, complex immune response makes it a challenge. Novel 
drug combinations have been tested in some endemic regions in order to lower 
the treatment cost and toxicity and preventing resistance gain by the parasite. 
Nitroquinolines were found to show leishmanicidal activity. Antimicrobial peptides 
including dermaseptin, andropin, and cecropin have been found effective against 
CL. Edelfosine is an oral drug with greatly increased activity compared to miltefo-
sine. There are also compounds isolated from plants which are tested and observed 
to have antileishmanial activity. For example, a polyphenolic flavanoid, quercetin, 
has shown antileishmanial activity in treatment of VL [57]. Four plant species 
named Agave americana, Azadirachta indica, Eclipta alba, and Piper longum showed 
important antileishmanial activity too [58–61].
Macrophage targeted drug delivery system is another novel approach to 
directly effect Leishmania parasites that live in the macrophages as their infection 
mechanism. As getting into macrophages is a challenge, liposomes, microspheres, 
nanoparticles, and carbon nanotubes are some of the various drug carriers that are 
studied to target macrophages [62]. In addition, use of specific receptors expressed 
by macrophages to actively deliver a drug is also used [63].
9. Conclusion and future perspectives
Leishmaniasis still remains as a big public health challenge in some parts of the 
world. Despite developments in scientific knowledge and medical technology, there 
is still a need for quick and cheap detection of Leishmania infections especially in 
endemic areas. Studies focusing on molecular microbiological methods can help to 
develop new diagnostic methods.
In terms of treatment of leishmaniasis, emerging resistance is a big threat 
for infectious disease specialists like in other microbial diseases. There are two 
arms of fight. One is the development of a successful vaccine, and the other 
is the progress of finding new compounds to cure the infection. If applicable 
early treatment should be applied in order to further prevent the spreading of 
the parasite. Having no effective human vaccines puts the disease at this critical 
point. That is why studies focusing on the development of vaccine will be path-
finder in the future decade. On the other hand, studies evaluating the antileish-
manial activity of various natural products or chemically modified compounds 
are needed to find new opportunities in successful treatment of Leishmania 
infections for the future.
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